News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma
Photo of Tom Powles taken from bartscancer.london
Apr 11, 2024, 08:13

Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma

Tom Powles, Director of Barts Cancer Center, recently shared on X:

“Trial in progress: The HER2/MMAE Antibody Drug Conjugates, Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma (HER2+ve). DVs efficacy looks increased also with Immuno-oncology (IO). Toxic profile looks distinct with? Decreased skin toxicity? EAU24 results will be considered in the context of other positives first line studies.”

Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma

Source: Tom Powles/X

Antibody drug conjugates Avelumab Barts Cancer Center cancer chemotherapy Disitimab EAU24 HER2 Immuno-oncology (IO) OncoDaily Oncology pembrolizumab Skin Toxicity Tom Powles Toxic profile Trial Vedotin
Special Coverage
Opinion
Dec 22, 2024, 05:38
BGICC 2025 Congress and Everything You Need to Know About Abstracts, Key Dates, and Deadlines
Blog
Dec 22, 2024, 05:31
Muhammad Bilal Abid: The Importance of Early Colon Cancer Screening
Blog
Dec 22, 2024, 05:28
Luis E Raez: Annual GO2 Foundation for Lung Cancer Walk/Run to raise funds and awareness
Blog
Dec 22, 2024, 05:25
Punita Khanna: Advances in breast cancer research, testing, treatment and therapies at the SABCS2024
Insight
Dec 22, 2024, 05:22
Camilla Perucchini: I have officially graduated with a Master of Science in Biotechnology curriculum
Career
Dec 22, 2024, 05:19
Sidra Naz has been honored with the 2025 Early Career Investigator Award in Healthcare Disparities Research in IBD
Blog
Dec 22, 2024, 05:17
Rasha Aboelhassan: Oncologists are overwhelmed by their own fights against cancer
Blog
Dec 22, 2024, 05:15
Jemma Arakelyan: Collaboration plans between City University of Hong Kong and Shenzhen Hospital of Southern Medical University
Blog
Dec 22, 2024, 05:13
The Connell and O’Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute
Blog
Dec 22, 2024, 05:05
Ruben Mesa: Excited to visit Atrium Health Levine Cancer Pineville
Blog
Dec 22, 2024, 05:02
Muhammad Umair Mushtaq: Are Stem Cell Transplants Safe for Myelofibrosis Patients Over 70?
Blog
Dec 22, 2024, 05:00
Elvina Almuradova: Being a part of Giuseppe Curigliano's team is an invaluable scientific milestone for me